Three things to know:
1. The arrangement includes Bioventus’ Durolane, Gelsyn-3 and Supartz FX hyaluronic acid-based treatments for knee OA.
2. Durolane is a single-injection, Gelsyn-3 is a three-injection, and Supartz FX is a five-injection joint fluid treatment.
3. Earlier this year Bioventus signed a nationwide contract with UnitedHealthcare to make Durolane and Gelsyn-3 available to employer and individual commercial plans, starting Oct. 1.
More articles on biologics:
Johns Hopkins, Carrum partnership grows to spine surgery
New York spine surgeon sentenced to probation, house arrest — 4 insights
11 PE transactions in orthopedics in 2019
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.